35. The method of claim 32 wherein the chlorotoxin is labeled.

36. The method of claim 35 wherein the chlorotoxin label is detected by enzyme-linked immunosorbent assay.

37. The method of claim 35 wherein the chlorotoxin label is a radiolabel.

38. The method of claim 37 wherein the radiolabel is selected from the group consisting of ^{3}H, ^{14}C, ^{32}P, ^{35}S, ^{36}Cl, ^{51}Cr, ^{57}Co, ^{58}Co, ^{59}Fe, ^{90}Y, ^{186}Re, ^{131}I and ^{125}I.

39. The method of any one of claims 37 or 38 wherein the radiolabel is detected by positron emission tomography scanning.

40. The method of claim 35 wherein the chlorotoxin label is a fluorescent moiety.

41. The method of claim 40 wherein the fluorescent moiety is selected from the group consisting of fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow.

42. The method according to claim 40 wherein the fluorescent moiety is detected by a method selected from the group consisting of fluorescent microscopy and fluorescent activated cell sorting.

43. The method of claim 35 wherein the chlorotoxin label is biotin.

44. The method of claim 43 further comprising the step of contacting the sample with avidin to form avidin-biotin-labeled chlorotoxin complexes.

45. The method of claim 44 further comprising the step of contacting the avidin-biotin-labeled chlorotoxin complexes with 3'3'-diaminobenzidine to form a colormetric product wherein the level of the colormetric product is indicative of the level of chlorotoxin binding.

46. The method of claim 32 wherein the tissue sample is frozen.

16 1
47. The method of claim 32 wherein the tissue sample is embedded in paraffin.

17 15 16
48. The method of any one of claims 46 or 47 wherein the tissue sample is counterstained.

18 17
49. The method of claim 48 wherein the counterstain is selected from the group consisting of methyl green, hematoxylin and eosin.--